DARA $0.80 some volume on this one today, could be related to HRTX move on their study results from " delayed-onset chemotherapy-induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents. "
DARA has KRN5500 for similar indication :
KRN5500 is a non-narcotic, non-opioid, intravenously administered new chemical entity (NCE) in development for painful chronic chemotherapy induced peripheral neuropathy (CCIPN). DARA is currently seeking a development and commercialization partner for KRN5500.
KRN5500 successfully completed a Phase 2a proof of concept study in patients with end-stage cancer, which met its primary endpoint of pain reduction relative to placebo (p = 0.03). Safety results from the study included clinically important gastrointestinal side effects, but no other major safety concerns were reported at doses that were much lower than those studied in earlier Phase 1 oncology trials completed under a National Cancer Institute (NCI) investigational new drug (IND) application for treatment of solid tumors.
The FDA has designated KRN5500 as a Fast Track Drug, and has granted DARA two separate Orphan Drug Designations for the treatment of multiple myeloma and for the parenteral treatment of painful, chronic chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics (CCIPN).
News 
Market Data 
Discover 
AI
